Fresnillo (LSE: FRES): Can the world’s largest silver miner hold its record gains as 2026 output dips?
TCS CEO corrects three major Nashik facts: Nida Khan was not HR head, unit not shut, no POSH complaints on record
Read More Pharma Industry News Is the next wave of obesity drugs moving beyond GLP-1? What Palatin, Rhythm, and Zealand are betting on Explore how Palatin Technologies, Rhythm Pharmaceuticals, and Zealand Pharma are shifting obesity drug development beyond GLP-1 into MC4R and amylin pathways. Read on. byVenkateshNovember 13, 2025